Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › pancreatic adenocarcinoma

Pancreatic adenocarcinoma

Part of Cancer

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for pancreatic adenocarcinoma

28 trials tracked for pancreatic adenocarcinoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 13 citations.

28Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 19 Phase 1 2 Other / NA 4
  1. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  2. Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Completed · 4 cited
  3. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  4. Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Completed
  5. Phase 2 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Completed
  6. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
Show 22 more trials
  1. Phase 2 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Completed
  2. Phase 2 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Completed
  3. Phase 2 Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Completed
  4. Phase 2 Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  5. Phase 2 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Completed
  6. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  7. Phase 2 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Completed
  8. Phase 2 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Completed
  9. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Completed
  10. Phase 2 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Completed
  11. Phase 2 Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma Completed
  12. Phase 2 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Completed
  13. Phase 2 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer Completed
  14. Phase 2 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  15. Phase 2 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  16. Phase 2 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Completed
  17. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  18. Phase 1 Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed
  19. N/A Pancreatic Juice Diagnosis From Duodenum Completed
  20. N/A Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer Completed
  21. N/A 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation Completed
  22. N/A The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pancreatic adenocarcinoma: what the trials found

Several chemotherapeutic agents have been evaluated for pancreatic adenocarcinoma. Capecitabine demonstrated comparable overall survival rates in both Phase II and Phase III assessments (p=0.62, p=0.38) 4. Gemcitabine was also studied, showing no significant difference in overall survival (p=0.72) or progression-free survival (p=0.91), while objective response rates varied across study arms (p=0.28) 15.

Fluorouracil has been evaluated in multiple trials; results showed no statistically significant difference in overall survival (p=0.15) 14, and a 42% R0 resection rate was observed at the two-year mark with an overall survival rate of 79% at one year 17. Nab-paclitaxel demonstrated varying objective response rates across different study groups, but showed consistent disease control in several cohorts (ranging from 55.6% to 81.3%) 7.

The EndoTAG-1 regimen did not show statistically significant differences in overall survival (p=0.6647), progression-free survival (p=0.4345), or objective response rates (p=0.2632) 6. Additionally, the use of eryaspase has been established in clinical trials for this condition 5.

Recent results — preliminary, needs further review

  • Paricalcitol (Zemplar) was associated with a significant reduction in serum levels of Carbohydrate Antigen 19-9 (CA19-9) (p=0.001) 1.
  • Paclitaxel Protein Bound (Abraxane) showed a statistically significant difference in R0 resection rates (p=0.017), though results for CA19-9 normalization and pathologic complete response were not statistically significant 2.
  • EUS FNA was evaluated as an intervention in recent clinical study 3.

For the clinician treating this condition

  • Standard chemotherapies including Capecitabine, Gemcitabine, and Fluorouracil have been established but did not show statistically significant improvements in survival metrics compared to respective controls in the reported trials.
  • Nab-paclitaxel demonstrated consistent disease control across multiple study arms 7.
  • Paricalcitol showed a statistically significant reduction in CA19-9 levels 1, and Abraxane showed a statistically significant difference in R0 resection rates 2.

AI synthesis of 10 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Oncology Meta-analysis
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
Sep 12, 2026
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Oncology Sys. Review
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Frontiers Aug 27, 2026
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Oncology RCT
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.
Aug 22, 2026
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients
Nutrition & Obesity Medicine Cohort
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients Diet patterns linked to outcomes in advanced pancreatic cancer patients
This retrospective observational study examined 210 patients with Stage III–IV pancreatic adenocarcinoma using real-world electronic medical…
Dietary patterns show links to treatment response and survival in advanced pancreatic cancer patients treated in real-world clinical setting…
Frontiers Apr 13, 2026

Research across Cancer

Related studies from across the Cancer family.

miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
Drug Pipeline Meta-analysis
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
Frontiers Oct 21, 2026
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma
Oncology Meta-analysis
Zanidatamab with chemotherapy or tislelizumab achieves 70% objective response rate in HER2-positive gastroesophageal adenocarcinoma New drug combination shows promise for advanced stomach cancer
This meta-analysis of 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma found that zanidatamab combined with chemothe…
A new drug combination shows a 70% response rate for patients with a specific type of advanced stomach cancer, though it carries some risks.
Oct 16, 2026
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers
Gastroenterology Sys. Review
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers Fungi may play a role in several types of cancer
This narrative review synthesizes evidence regarding fungal dysbiosis in colorectal cancer, gastric cancer, and pancreatic ductal adenocarci…
New research explores how fungal imbalances in the body might link to colorectal, gastric, and pancreatic cancers.
Frontiers Oct 8, 2026
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitor and chemotherapy combination improves pathological response in gastric adenocarcinoma Immune therapy combined with chemotherapy improves gastric cancer outcomes
This systematic review and meta-analysis of 74 trials evaluates neoadjuvant and perioperative strategies for locally advanced gastric and ga…
Adding immune checkpoint inhibitors to chemotherapy can significantly improve response rates and survival for patients with advanced stomach…
Frontiers Sep 25, 2026
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma
Pulmonology & Critical Care Sys. Review
Pulmonary lymphangitic carcinomatosis may mimic interstitial lung disease in patients with gastric adenocarcinoma Lung cancer can mimic common lung diseases in young men
This case report and review of the literature describes a 33-year-old male with gastric adenocarcinoma and pulmonary lymphangitic carcinomat…
A 33-year-old man with a lung condition that looked like a common disease was actually a rare form of cancer.
Frontiers Sep 25, 2026
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
Oncology Meta-analysis
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
Frontiers Sep 19, 2026
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Oncology Guideline
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Frontiers Sep 14, 2026
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Oncology Guideline
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Frontiers Sep 13, 2026
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
Oncology Meta-analysis
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Sep 6, 2026
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Gastroenterology Meta-analysis
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
Sep 1, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026